drugset / Trial / NCT05905913
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple intravenous ascending doses of ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases, alone and in combination with meropenem in healthy subjects.
Timeline
- Start
- 2023-04-12
- Primary completion
- 2024-01-05
- Completion
- 2024-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANT3310 | Unknown | — | Intravenous |
| Subject | Meropenem | Small molecule | — | Intravenous |
Indications
No indication recorded.